Clinical Trials
18 trialsNCT00596648 2026-01-13
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Exelixis
Phase 1/2 Completed
NCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01068587 2023-08-04
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT00602030 2022-08-22
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Syndax Pharmaceuticals
Phase 1/2 Completed
NCT01455389 2022-03-02
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Genprex, Inc.
Phase 1/2 Terminated
NCT01211483 2021-06-16
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 1/2 Completed
NCT00278148 2020-07-20
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT02155465 2019-01-16
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00390429 2018-12-06
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT00043823 2018-11-07
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00280150 2017-06-19
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00408499 2017-05-08
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
University of California, Davis
Phase 1/2 Completed
NCT00994123 2016-08-22
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Merrimack Pharmaceuticals
Phase 1/2 Completed
NCT00826449 2016-06-28
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00716456 2015-04-30
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02044601 2014-04-24
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT00522938 2012-06-28
Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Chroma Therapeutics
Phase 1/2 Terminated
NCT00387322 2010-03-29
Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed